{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:08:18Z","timestamp":1781500098461,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T00:00:00Z","timestamp":1518825600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-COHO-002 Observatoire Fran\u00e7ais de la Scl\u00e9rose en Plaques (OFSEP)"],"award-info":[{"award-number":["ANR-10-COHO-002 Observatoire Fran\u00e7ais de la Scl\u00e9rose en Plaques (OFSEP)"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["by the Eugene Devic Foundation against Multiple Sclerosis (EDMUS Foundation)"],"award-info":[{"award-number":["by the Eugene Devic Foundation against Multiple Sclerosis (EDMUS Foundation)"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s00415-018-8771-5","type":"journal-article","created":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T02:10:13Z","timestamp":1518833413000},"page":"917-925","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study"],"prefix":"10.1007","volume":"265","author":[{"name":"On behalf of Francophone Society of Multiple Sclerosis and OFSEP investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Cabre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mejdoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Jeannin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Merle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Plumelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Cavillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Smadja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Marignier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,17]]},"reference":[{"key":"8771_CR1","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","volume":"53","author":"DM Wingerchuk","year":"1999","unstructured":"Wingerchuk DM, Hogancamp WF, O\u2019Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic\u2019s syndrome). Neurology 53:1107\u20131114","journal-title":"Neurology"},{"key":"8771_CR2","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker of optic-spinal multiple sclerosis binds the aquaporin-4 water channel. J Exp Med 202:433\u2013437","journal-title":"J Exp Med"},{"key":"8771_CR3","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1212\/01.wnl.0000303817.82134.da","volume":"70","author":"M Matiello","year":"2008","unstructured":"Matiello M, Lennon VA, Jacob A et al (2008) NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 70:2197\u20132200","journal-title":"Neurology"},{"key":"8771_CR4","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/ana.20770","volume":"59","author":"BG Weinshenker","year":"2006","unstructured":"Weinshenker BG, Wingerchuk DM, Vukusic S et al (2006) Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 59:566\u2013569","journal-title":"Ann Neurol"},{"key":"8771_CR5","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1093\/brain\/awn240","volume":"131","author":"S Jarius","year":"2008","unstructured":"Jarius S, Aboul-Enein F, Waters P et al (2008) Antibody to aquaporin-4 in the long term course of neuromyelitis optica. Brain 131:3072\u20133080","journal-title":"Brain"},{"key":"8771_CR6","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1177\/1352458508092811","volume":"14","author":"B Weinstock-Guttman","year":"2008","unstructured":"Weinstock-Guttman B, Miller C, Yeh EA et al (2008) Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica. Mult Scler 14:1061\u20131067","journal-title":"Mult Scler"},{"key":"8771_CR7","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.bbrc.2009.06.085","volume":"386","author":"M Kinoshita","year":"2009","unstructured":"Kinoshita M, Nakatsuji Y, Kimura T et al (2009) Neuromyelitis optica: passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun 386:623\u2013627","journal-title":"Biochem Biophys Res Commun"},{"key":"8771_CR8","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/ana.21837","volume":"66","author":"M Bradl","year":"2009","unstructured":"Bradl M, Misu T, Takahashi T et al (2009) Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 66:630\u2013643","journal-title":"Ann Neurol"},{"key":"8771_CR9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ana.21802","volume":"66","author":"JL Bennett","year":"2009","unstructured":"Bennett JL, Lam C, Kalluri SR et al (2009) Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 66:617\u2013629","journal-title":"Ann Neurol"},{"key":"8771_CR10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/brain\/awp309","volume":"133","author":"S Saadoun","year":"2010","unstructured":"Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC (2010) Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 133:349\u2013361","journal-title":"Brain"},{"key":"8771_CR11","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nrd2085","volume":"5","author":"JL Browning","year":"2006","unstructured":"Browning JL (2006) B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 5:564\u2013576","journal-title":"Nat Rev Drug Discov"},{"key":"8771_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/rheumatology\/keh446","volume":"44","author":"JC Edwards","year":"2005","unstructured":"Edwards JC, Cambridge G (2005) Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology (Oxford) 44:151\u2013156","journal-title":"Rheumatology (Oxford)"},{"key":"8771_CR13","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1196\/annals.1313.014","volume":"1050","author":"BF Hoyer","year":"2005","unstructured":"Hoyer BF, Manz RA, Radbruch A, Hiepe F (2005) Long-lived plasma cells and their contribution to autoimmunity. Ann N Y Acad Sci 1050:124\u2013133","journal-title":"Ann N Y Acad Sci"},{"key":"8771_CR14","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","volume":"64","author":"BA Cree","year":"2005","unstructured":"Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64:1270\u20131272","journal-title":"Neurology"},{"key":"8771_CR15","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","volume":"65","author":"A Jacob","year":"2008","unstructured":"Jacob A, Weinshenker BG, Violich I et al (2008) Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 65:1443\u20131448","journal-title":"Arch Neurol"},{"key":"8771_CR16","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1177\/1352458515602337","volume":"22","author":"N Collongues","year":"2016","unstructured":"Collongues N, Brassat D, Maillart E et al (2016) Efficacy of Rituximab in refractory in neuromyelitis optica. Mult Scler 22:955\u2013959","journal-title":"Mult Scler"},{"key":"8771_CR17","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","volume":"76","author":"HL Pellkofer","year":"2011","unstructured":"Pellkofer HL, Krumbholz M, Berthele A et al (2011) Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76:1310\u20131315","journal-title":"Neurology"},{"key":"8771_CR18","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","volume":"68","author":"SH Kim","year":"2011","unstructured":"Kim SH, Kim W, Li XF, Jung IJ, Kim HJ (2011) Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 68:1412\u20131420","journal-title":"Arch Neurol"},{"key":"8771_CR19","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","volume":"73","author":"V Damato","year":"2016","unstructured":"Damato V, Evoli A, Ioro R (2016) Efficacy and safety of rituximab therapy in Neuromyelitis optica spectrum disorders. JAMA Neurol 73:1342\u20131348","journal-title":"JAMA Neurol"},{"key":"8771_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennet JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177\u2013189","journal-title":"Neurology"},{"key":"8771_CR21","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti SF, Pittock SJ, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485\u20131489","journal-title":"Neurology"},{"key":"8771_CR22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jns.2017.01.025","volume":"373","author":"M Cohen","year":"2017","unstructured":"Cohen M, Romero G, Bas J et al (2017) Monitoring CD27+ B cells in neuromyelitis optica spectrum disorders patients treated with rituximab. Results from a bicentric study. J Neurol Sci 373:335\u2013338","journal-title":"J Neurol Sci"},{"key":"8771_CR23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jocn.2015.08.033","volume":"26","author":"Y Dai","year":"2016","unstructured":"Dai Y, Lu T, Wang Y et al (2016) Rapid exacerbation of neuromyelitis optica after rituximab treatment. J Clin Neurosci 26:168\u2013170","journal-title":"J Clin Neurosci"},{"key":"8771_CR24","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.jocn.2010.12.011","volume":"18","author":"I Nakashima","year":"2011","unstructured":"Nakashima I, Takahashi T, Cree BA et al (2011) Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. J Clin Neurosci 18:997\u2013998","journal-title":"J Clin Neurosci"},{"key":"8771_CR25","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1172\/JCI18025","volume":"112","author":"DT Avery","year":"2003","unstructured":"Avery DT, Kalled SL, Ellyard JI et al (2003) BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 112:286\u2013297","journal-title":"J Clin Invest"},{"key":"8771_CR26","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","volume":"72","author":"SH Kim","year":"2015","unstructured":"Kim SH, Jeong IH, Yhun JH et al (2015) Treatment outcomes with rituximab in 100 patients with neuromyelitis optica. Influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol 72:989\u2013995","journal-title":"JAMA Neurol"},{"key":"8771_CR27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.4161\/mabs.1.6.9884","volume":"6","author":"JR Berger","year":"2009","unstructured":"Berger JR, Houff SA, Major EO (2009) Monoclonal antibodies and progressive multifocal leukoencephalopathy. mAbs 6:583\u2013589","journal-title":"mAbs"},{"key":"8771_CR28","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/archneurol.2010.203","volume":"67","author":"DB Bichuetti","year":"2010","unstructured":"Bichuetti DB, Lobato de Oliveira EM, Oliveira DM, Amorin de Souza N, Gabbai AA (2010) Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol 67:1131\u20131136","journal-title":"Arch Neurol"},{"key":"8771_CR29","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","volume":"66","author":"A Jacob","year":"2009","unstructured":"Jacob A, Matiello M, Weinshenker BG et al (2009) Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 66:1128\u20131133","journal-title":"Arch Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-018-8771-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-8771-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-8771-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,16]],"date-time":"2019-02-16T22:35:49Z","timestamp":1550356549000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-018-8771-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,17]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["8771"],"URL":"https:\/\/doi.org\/10.1007\/s00415-018-8771-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,17]]},"assertion":[{"value":"6 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"I (Philippe Cabre) assume that none of the authors had a conflict of interest with the content of the present study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The ethics committee of Fort de France approved this study. All samples were stored at \u221280 \u00b0C at CERBIM (CHU Martinique) that has been labelled by French Ministry of Health.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard"}}]}}